抗体筛查。

Antibody Screening.

机构信息

Department of Pediatric Oncology/Hematology, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Adv Exp Med Biol. 2019;1188:149-163. doi: 10.1007/978-981-32-9755-5_8.

DOI:10.1007/978-981-32-9755-5_8

PMID:31820387

Abstract

Antibodies are among the most frequently used tools in research and have had a profound impact on the discovery of diagnostic and therapeutic targets and the understanding of the molecular background of diseases. In particular in reverse phase protein arrays (RPPA), where there is no separation of the proteins according to molecular weight, it is crucial that antibodies are proven to be highly specific, selective, and reproducible. However, numerous studies have shown that many antibodies frequently do not recognize the protein that they are supposed to detect, that multiple antibodies do often function in one application but not in another, and that antibodies are not stable over time or between different batches. So far, no universally accepted guidelines or standardized methods for determining the validity of antibodies have been established. This chapter discusses the urgent need for antibody validation, current strategies that are used for (RPPA) antibody validation, as well as proposes a new strategy about how to report, score, and integrate antibody validation from multiple users.

摘要

抗体是研究中最常使用的工具之一，对诊断和治疗靶点的发现以及对疾病分子背景的理解产生了深远的影响。特别是在反相蛋白阵列（RPPA）中，由于蛋白质没有根据分子量进行分离，因此抗体具有高度特异性、选择性和可重复性至关重要。然而，许多研究表明，许多抗体经常不能识别它们应该检测到的蛋白质，许多抗体在一种应用中经常起作用而在另一种应用中不起作用，并且抗体在不同批次之间不稳定。到目前为止，还没有建立普遍接受的抗体有效性确定指南或标准化方法。本章讨论了抗体验证的迫切需要，当前用于（RPPA）抗体验证的策略，以及提出了一种如何从多个用户报告、评分和整合抗体验证的新策略。